Navigation Links
Horizon Therapeutics Initiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501
Date:10/8/2007

- Ongoing Phase 3 clinical development program will examine HZT-501 as a

potential new 'GI-friendly' NSAID for mild to moderate pain -

PALO ALTO, Calif., Oct. 8 /PRNewswire/ -- Horizon Therapeutics, Inc., a privately held biopharmaceutical company, today announced that it has initiated a phase 3 follow-on safety study (protocol HZ-CA-304) of its lead product candidate HZT-501, an investigational prescription NSAID (non-steroidal anti-inflammatory drug) designed to be "GI-friendly".

HZT-501 is a proprietary formulation of ibuprofen, the most prescribed NSAID in the United States, combined with famotidine, the most potent H2 receptor antagonist, in a single pill. HZT-501 is specifically designed to provide pain relief while reducing stomach acidity during the peak time of risk for gastric ulceration. In a randomized pilot clinical study published in The New England Journal of Medicine (Taha, et. al May 1996), famotidine was demonstrated to significantly reduce the incidence of gastric and duodenal ulcers vs. placebo when administered together with NSAIDs.

"This study is designed to examine the long-term safety of HZT-501 as part of the overall clinical trial program," said George F. Tidmarsh, M.D., Ph.D., co-founder and chief executive officer of Horizon Therapeutics. "We hope that the trial results offer patients, physicians and regulatory authorities a robust set of data to evaluate HZT-501."

The safety study will support the two ongoing pivotal phase 3 trials involving a total of 1,400 patients with mild-to-moderate pain, including patients with osteoarthritis. Horizon protocols HZ-CA-301 and HZ-CA-303 will evaluate the efficacy and safety of HZT-501 with the primary endpoint being reduction in the risk of development of ibuprofen-associated upper gastrointestinal ulcers in patients who require the use of ibuprofen. The trials began in March 2007, and an NDA is targeted to be filed Q4 2008.

The HZ-CA-304 phase 3 follow-on safety study is a multi-center, double blind trial that will enroll approximately 200 patients who have participated in the 301 or 303 phase 3 trials. Study participants will continue to receive the same study medication they received in the other trials which was either HZT-501 (ibuprofen 800 mg/famotidine 26.6 mg) or ibuprofen 800 mg. Study participants will receive medication for up to 28 weeks.

About the Pain Market

HZT-501 targets the widespread medication void in the mild-to-moderate pain market left by COX-2 inhibitors which have either been taken off the market or are being prescribed less frequently due to elevated cardiovascular risk. From 2004 to 2006, the U.S. NSAID market grew over 20 percent to 73 million prescriptions. Over 26 million ibuprofen prescriptions are now written annually in the United States alone.

However, while commonly prescribed to treat pain, NSAIDs have been linked to serious gastrointestinal (GI) side effects in up to 25 percent of all chronic arthritis patients. NSAID-induced GI toxicity causes an estimated 16,000 deaths and more than 100,000 hospitalizations annually in the United States. Despite this, studies have shown that as low as 30% of high-risk patients are commonly co-prescribed a gastro-protective agent in combination with their NSAID. In addition, patient adherence to a regimen of separate GI protective and pain medications has also been shown to be poor.

About Horizon Therapeutics

Horizon Therapeutics, Inc. is a late stage biopharmaceutical company focused on the rapid development and commercialization of therapeutic treatments for mild-to-moderate pain management. The Company is building a novel portfolio of therapies through innovative combinations of approved pharmaceutical products that seek to improve safety, efficacy, and patient compliance. Its lead product candidate, HZT-501, entered Phase 3 trials in 2007. In addition to HZT-501, Horizon has a pipeline of follow-on pain combination products in earlier stages of development. For more information visit http://www.horizontherapeutics.com.


'/>"/>
SOURCE Horizon Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/8/2017)... Second-quarter 2017 revenues of $876 million ... continuing operations Second-quarter 2017 ... million Second-quarter 2017 Sterile ... Second-quarter 2017 adjusted diluted earnings ... to $0.93 Second-quarter 2017 ...
(Date:8/7/2017)... , Aug. 7, 2017  Endo International plc ... reached agreements to resolve virtually all known U.S. mesh ... discussions to resolve the known remaining U.S. claims at ... payments beginning in the fourth quarter of 2017 and ... of its second quarter 2017 results, the Company intends ...
(Date:8/2/2017)... , Aug. 2, 2017   Marshall County Hospital in Benton, Kentucky ... reduce the risk of hospital-acquired infections (HAIs). The new addition, Tru-D SmartUVC , short ... to kill deadly pathogens such as C. diff , MRSA, MERS, Ebola and more. ... Tru-D SmartUVC ... Tru-D in action in a patient room ...
Breaking Medicine Technology:
(Date:8/18/2017)... ... 18, 2017 , ... Moore Insurance, a Houston area agency ... is launching a regional charity effort to provide publicity assistance and generate donations ... Tumor Foundation (PBTF) has raised nearly $30 million in donations that has been ...
(Date:8/18/2017)... ... August 18, 2017 , ... Goss & Associates ... residential and commercial clients in the greater Houston region, is helping locally recognized ... the fight against cancer. , Founded by Tony and Amber Bender after losing ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... practitioners specializing in bioidentical hormone replacement therapy and integrative medicine, has become a ... conditions of aging, such as menopause, andropause, thyroid disorder and adrenal insufficiencies. ...
(Date:8/18/2017)... ... 18, 2017 , ... Inc. magazine has ranked American Specialty Health, Incorporated (ASH) ... nation's fastest-growing private companies. This marks the eighth time in the last nine years ... year’s ranking reflects ASH’s 76 percent overall revenue growth from 2013 ($239 million) through ...
(Date:8/18/2017)... ... August 18, 2017 , ... “Dangerous Inheritance”: a mystery about saving the ... Diane is from Southwest Nebraska where she was raised on a farm. As ... story is fictional, but the friendships and mantra of ‘neighbors helping neighbors’ have always ...
Breaking Medicine News(10 mins):